How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?

@inproceedings{Tombal2005HowGD,
  title={How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?},
  author={Bertrand F. Tombal and Richard Berges},
  year={2005}
}
Abstract Following the discovery that prostate tumour growth is androgen-dependent, androgen suppression as achieved with orchiectomy (standard of castration) has been shown to delay tumour progression, improve symptoms and disease specific survival. Since the seventies hormone therapy with luteinising hormone releasing hormone (LHRH) agonists has constituted the main approach for suppressing testosterone in the treatment of advanced and metastatic prostate cancer. The availability of sustained… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Experience with degarelix in the treatment of prostate cancer

VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.

VIEW 1 EXCERPT
CITES BACKGROUND